Cardiovascular Medicine - Active Clinical Trials
Clinical Trails Currently Enrolling
To refer a patient to any cardiovascular medicine trial, page the on-call pager number at (573) 499-8084.
| Trial |
Investigators |
Description |
| CANTOS |
Drs. Webel/Aggarwal/Kumar |
Canakinumab vs. Placebo in the prevention of recurrent cardiovascular events in Post-MI patients with elevated hsCRP |
| EXACT-HF |
Drs. Flaker/Dohrmann |
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients using Allopurinol vs. Placebo |
| PEGASUS--TIMI 54 |
Drs. Aggarwal/Kumar |
Ticagrelor vs. Placebo to assess the prevention of thrombotic events in patients 1-3 years post MI |
| RAID |
Drs. Flaker/Weachter |
Late Sodium Current Blockade in High-Risk ICD patients using Ranolazine vs. Placebo |
Registry Trials - Currently Enrolling
| Trial |
Investigators |
Description |
| ACTION |
Dr. Aggarwal |
Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines |
| Medtronic--PPP/AAF |
Drs. Weachter/Flaker |
Post-market surveillance to document product performance assessment of Medtronic device leads |
| Pre-Determine |
Dr. Flaker |
Observational prospective study to identify genetic markers & biomarkers that predict the risk of arrhythmic death among CAD patients with preserved left ventricular ejection fraction (LVEF >35%) |
Ongoing Clinical Trials - Not Enrolling
|
Trial
|
Investigators
|
Description
|
| AVERROES--LTOLE |
Drs. Weachter/Flaker |
Apixaban vs. Aspirin to prevent stroke in A-fib patients unsuitable for warfarin. Long term open label extension |
| AQUARIUS |
Drs. Webel/Aggarwal/Kumar |
Aliskiren vs. Placebo to evaluate efficacy on the progression of atherosclerosis via coronary intravascular ultrasound |
| IMPROVE-IT |
Drs. Aggarwal/Weachter/Flaker |
Vytorin vs. Simvastatin in High Risk subjects presenting with ACS |
| REVEAL TIMI--55 |
Drs. Aggarwal/Webel |
Does inhibition of cholesteryl ester transfer protein (Anacetrapib vs. Placebo) prevent major vascular events in patients with vascular disease? |
| SOLID TIMI--52 |
Drs. Aggarwal/Kumar/Senthilkumar |
Darapladib (Lp-PLA2 inhibitor) vs. placebo in acute coronary syndrome to compare the incidence of major cardiovascular adverse events |
| TRANSLATE--ACS |
Dr. Webel |
Observational prospective study to assess treatment with ADP receptor inhibitors after hospitalization with an ACS event |
|
